Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Review of the Use of Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Malignancy in Pediatric Patients.

Cancers·2023
Same author

<i>In Situ</i> Study of Structure Formation under Stress in Stretchable Conducting Nanocomposites.

The journal of physical chemistry letters·2023
Same author

SARS-CoV-2 vaccination induced cerebral venous sinus thrombosis: Do megakaryocytes, platelets and lipid mediators make up the orchestra?

Free neuropathology·2023
Same author

The Role of Montelukast Sodium in Children with Adenoid Hypertrophy - A Comparative Study.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India·2023
Same author

AIE-active cyclometalated iridium(III) complexes for the detection of lipopolysaccharides and wash-free imaging of bacteria.

Dalton transactions (Cambridge, England : 2003)·2023
Same author

Comparison of Radiological and Clinical Outcomes between Expandable and Non-expandable Cages Following Cervical Corpectomy: A Systematic Review and Meta-analysis.

Asian spine journal·2023
Same journal

Erratum: A multimodal intelligent model for the noninvasive prediction of vascular endothelial growth factor expression and prognostic stratification in breast cancer: A multicenter retrospective study.

Journal of cancer research and therapeutics·2026
Same journal

Erratum: Consensus from the Asian conference on tumor ablation working group on image-guided thermal ablation for lung tumor: 10 key questions and answers.

Journal of cancer research and therapeutics·2026
Same journal

Cryoablation for plantar alveolar soft part sarcoma: A case report.

Journal of cancer research and therapeutics·2026
Same journal

Efficacy and safety of Xihuang pill/capsule as adjuvant therapy for lung cancer: A systematic review and meta-analysis.

Journal of cancer research and therapeutics·2026
Same journal

Extracellular volume fraction determined by equilibrium contrast-enhanced dual-energy CT as a diagnostic indicator in patients with renal masses.

Journal of cancer research and therapeutics·2026
Same journal

Enhancing non-invasive colorectal cancer screening with stool DNA methylation markers and light gradient-boosting machine learning.

Journal of cancer research and therapeutics·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Geftinib.

Ajay Gupta1, Vinod Raina

  • 1Department of Medical Oncology, DrBRA Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India. ajayajaygupta2002@rediffmail.com

Journal of Cancer Research and Therapeutics
|December 2, 2010
PubMed
Summary
This summary is machine-generated.

Gefitinib shows promise for treating lung cancer, particularly in patients with EGFR mutations. This targeted therapy offers good clinical responses with low toxicity, even in severe cases.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Experiment Videos

Last Updated: Jun 6, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Gefitinib is a targeted therapy inhibiting the epidermal growth factor receptor (EGFR).
  • EGFR mutations are key biomarkers for predicting response to gefitinib in lung cancer.
  • Current use often involves patients refractory to chemotherapy, with trials exploring earlier use.

Purpose of the Study:

  • To review the efficacy and safety of gefitinib in lung cancer treatment.
  • To highlight patient populations and genetic profiles associated with positive responses.
  • To discuss the potential of gefitinib in advanced or refractory lung cancer.

Main Methods:

  • Extensive literature search using PubMed and Medline databases.
  • Review of clinical trial data and published studies on gefitinib.
  • Analysis of factors influencing gefitinib response, including EGFR mutations.

Main Results:

  • Gefitinib demonstrates significant clinical response rates in patients with EGFR mutations.
  • Favorable outcomes observed in never-smokers, Asian patients, and those with adenocarcinoma.
  • Potential for dramatic "Lazarus responses" in patients with poor performance status.
  • Gefitinib is associated with generally low toxicity.

Conclusions:

  • Gefitinib is an effective targeted therapy for specific lung cancer patient groups.
  • Understanding EGFR pathways is crucial for developing advanced lung cancer treatments.
  • Further research is exploring gefitinib as a first-line therapy and in elderly populations.